Bafiertam

Active Ingredient(s): Monomethyl Fumarate
FDA Approved: * April 28, 2020
Pharm Company: * BANNER LIFE SCIENCES
Category: Multiple Sclerosis

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Bafiertam Overview

Monomethyl fumarate, sold under the brand name Bafiertam is a medication for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[1] It was approved for medical use in the United States in April 2020.[2] The most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea.[1] Contents 1 Pharmacology 2 Na...

Read more Bafiertam Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Monomethyl_fumarate

Recent Bafiertam Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Monomethyl Fumarate
  • Capsule, Delayed Release: 95mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Bafiertam: (1 result)

Sorted by National Drug Code
  • 69387-001 Bafiertam 95 mg Oral Capsule by Banner Life Sciences LLC

Other drugs which contain Monomethyl Fumarate or a similar ingredient: (1 result)